Skip to main content

Generic-drug manufacturer Kern Pharma has acquired Gynea Laboratoris, a pharmaceutical company specializing in products for women’s health. This transaction demonstrates Kern Pharma’s desire to grow and expand its product line in gynecology. Although they have acquired 100% of the business, Kern will keep the Gynea structure as an independent company.

Gynea is a pharmaceutical company based in Palau Solità i Plegamans, specializing in gynecology. They manufacture products that encompass various phases of women’s health, like premenstrual syndrome, pre-conception and anti-conception, pregnancy, breastfeeding and menopause, among others. Founded in 1999, the company currently posts turnover of €10 millions, 10% of which comes from abroad.

According to Raúl Díaz-Varela, CEO of Kern Pharma, this operation addresses two main focal points in the company’s business plan: developing new products and expanding internationally. The Terrassa-based pharmaceutical company is part of the Indukern Group, a Spanish group with subsidiaries in 19 different countries.

More information is available in the Kern Pharma press release.

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.